Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.
Pattern Computer is a Washington-based AI company that builds a 'Pattern Discovery Engine' - a system designed to surface novel, higher-order patterns in complex, high-dimensional data that conventional tools and even exascale computers miss. Founded by technology forecaster Mark Anderson and a team that includes an Autodesk co-founder, the company focuses first on medical research and diagnostics, where its technology has improved cancer-screening accuracy and powered a reagent-free, near real-time COVID-19 test.
Watershed Bio (legally Watershed Informatics) is a Cambridge, Massachusetts startup building a unified, cloud-based platform for biological data analysis. Its product, Omics Bench, lets biologists and bioinformaticians securely store, harmonize, and analyze multi-omic data - genomics, single-cell and spatial transcriptomics, epigenomics, proteomics, metabolomics, microbial sequencing and protein folding - using customizable and AI-assisted workflows backed by elastic supercomputing. The pitch: go from sample to therapeutic insight in a single day instead of weeks, closing the gap between high-code and no-code bioinformatics for drug-discovery teams.
Robert K. Weigle is a medical device and diagnostics executive with more than 25 years of experience taking healthcare products from pre-clinical research to commercial launch. He is CEO of NOW Diagnostics, an independent board member of Tenon Medical, and a former entrepreneur-in-residence at DigitalDx Ventures. He led Benvenue Medical as CEO for over a decade, raising more than $200 million and launching spine devices in two markets, and later ran saliva-based diagnostics companies focused on cancer detection. His career spans Fortune 500 names like Johnson & Johnson and Baxter as well as a string of venture-backed startups.
Manifold is a Boston-area applied-AI company building a vertical agent platform for life sciences. Its software helps pharma companies, molecular diagnostics firms, biobanks and academic medical centers turn messy multimodal biomedical data into governed, analysis-ready insight - compressing workflows that used to take months into minutes, while keeping the data governance that regulated research demands. Founded in 2016 and led by CEO Vinay Seth Mohta, the company raised an $18M Series B in December 2025, bringing total funding to roughly $40M.
Vik Vaz is a physician-turned-executive who became CEO and President of San Diego multi-omics biotech Pleno Inc. in December 2024, arriving the same day the company closed a $25M Series B. Trained as a surgeon and interventional oncologist, he later ran strategy and companion diagnostics at Illumina and was a partner at both McKinsey and Boston Consulting Group. At Pleno he is commercializing the RAPTOR platform, which uses proprietary Hypercoding technology to detect DNA, RNA and protein targets in a single sample at high speed and low cost.
Tom Schoenherr is CEO of Diagnostics at Tempus AI, the publicly traded precision-medicine company. He previously ran Ambry Genetics as CEO from 2021 to 2025, steering it through a definitive agreement to be acquired by Tempus. He has spent more than 25 years inside molecular diagnostics, with prior leadership stints at Counsyl, Quest Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Omada Health.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
insitro is a machine-learning-driven drug discovery and development company that uses high-content human data, cellular models and AI to find better targets and design better medicines. Founded in 2018 by Daphne Koller, the company runs its own therapeutic pipeline and partners with large pharma on programs in ALS, metabolic disease and oncology.
Profluent is an AI-first protein design company building frontier models that author novel proteins - including the first AI-designed CRISPR gene editor, OpenCRISPR-1. Based in Berkeley's biotech corridor, the company applies the same scaling-law playbook that worked for language models to the language of biology, then validates the outputs in a wet lab.
Jason Pontin is a General Partner at DCVC (Data Collective Venture Capital) in Palo Alto, where he leads communications and originates investments in early-stage computational biology and chemistry startups. A former journalist who spent 13 years transforming MIT Technology Review into a digital-first powerhouse and three years as Senior Partner at Flagship Pioneering, Pontin brings rare storytelling and scientific fluency to deep tech investing. He co-founded Totus Medicines, a chemical biology company targeting brain cancer, and sits on boards of companies working on DNA synthesis, AI-driven drug discovery, water purification, and lab automation.
Mohan Iyer is a General Partner at SOSV's IndieBio SF, the world's leading biotech accelerator. With 25+ years operating life science startups across Genentech, Tethys Bioscience, Second Genome, and Pendulum Therapeutics, he brings rare bench-to-boardroom experience to pre-seed biotech founders. Trained as a chemical and biomedical engineer before earning his MBA from Yale, Iyer has spent his career translating disruptive biology into products the world actually needs — and now bets on founders doing the same.
J. Seth Strattan, PhD is a General Partner at Two Bear Capital, a Whitefish, Montana-based venture capital firm investing at the crossroads of life sciences and technology. With a PhD in Structural Biology and a BA in Philosophy from Stanford University, Strattan spent years at Stanford building and leading the engineering and data science teams behind landmark genomics consortia - ENCODE, the Human Cell Atlas, and the International Human Epigenomics Consortium - before pivoting to back the founders tackling biology's hardest problems. He is based in Silicon Valley, leads Two Bear Capital's Menlo Park office, and splits his remaining time between Montana and a family farm in the Appalachian Mountains of Kentucky.
Stuart Peterson is the Founder and Managing General Partner of ARTIS Ventures, a San Francisco-based venture capital firm he launched in 2001 that coined and trademarked the term 'TechBio.' A 2017 Forbes Midas List honoree, Peterson led early-stage investments in YouTube (acquired by Google) and StemCentrx (acquired by AbbVie for $10.2 billion - the largest-ever venture-backed life sciences acquisition), and has since focused ARTIS at the convergence of computer science and life science, closing a $200 million TechBio II Fund in December 2023 to back next-generation health and medicine companies deploying AI, machine learning, and deep learning to transform human health.
Dr. Gauri Naik is a Ph.D. biotechnologist, serial entrepreneur, and Co-Founder & CEO of OptraHEALTH, a Silicon Valley AI health-tech company building conversational AI and revenue cycle automation tools for genetics, genomics, and clinical workflows. With 11 U.S. patents, a career spanning digital pathology (BioImagene, acquired by Roche), and products deployed at leading health systems across the US, Europe, and Asia, she sits at the intersection of molecular biology, machine learning, and enterprise health IT.
Kim Kelderman is the President and CEO of Bio-Techne Corporation, a global life science tools and diagnostics company headquartered in Minneapolis, Minnesota. With over 30 years of healthcare and life sciences experience, Kelderman rose through the ranks at Bio-Techne after joining in 2018 to lead the Diagnostics and Genomics segment, where he doubled the spatial biology business and commercialized the ExoDx Prostate test. A native of the Netherlands educated at Hogeschool Heerlen and Columbia Business School, he previously held executive roles at Thermo Fisher Scientific and Becton Dickinson. He became CEO on February 1, 2024, succeeding Chuck Kummeth.
Marc Montserrat is the Chief Executive Officer of DNA Script, a French-American biotech pioneering enzymatic DNA synthesis - a technology that lets labs print custom DNA on demand, in hours instead of days. A Wharton MBA and industrial engineer by training, Montserrat spent two decades building commercial operations at Ariosa Diagnostics (prenatal testing), Omniome (next-gen sequencing), and Deepcell (AI-powered single-cell analysis) before co-founding Splice Bio and ultimately landing as CEO of DNA Script in October 2024. He was drawn into life sciences after a misdiagnosis scare at 24 that convinced him life was too short to spend on work without meaning.
Alec Ford is the chief executive of Karius, a Redwood City genomics-diagnostics company that reads microbial cell-free DNA from a single tube of blood to identify more than a thousand pathogens. He took the job in October 2020 and led the company through a $100M Series C in May 2024.
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.
Elaine Cheung is Chief Business Officer at Moonwalk Biosciences, a South San Francisco biotech backed by $57 million in funding and co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis. With 20+ years navigating the inflection points of genomic medicine - from spinning GRAIL out of Illumina, helping architect its $900M+ Series B, and steering Lyell Immunopharma through its IPO - Cheung brings a rare combination of scientific literacy and deal-making precision. At Moonwalk, she is helping build the business infrastructure for a company that has pivoted from epigenetic editing to siRNA-based therapeutics targeting adipose biology and obesity.
Eric Green is the Founder and CEO of Trace Neuroscience, a South San Francisco biotech company racing to develop the first effective ASO therapy for ALS. A Harvard-and-Stanford-trained physician-scientist with a background in cardiology, Green co-founded iLab Solutions (acquired by Agilent), Respira Design (Stanford $50K Challenge winner), and Maze Therapeutics before launching Trace with a $101 million Series A in November 2024. Trace's lead program targets UNC13A - a protein lost in ALS patients - using an antisense oligonucleotide designed to restore healthy nerve-muscle communication. With clinical trials targeting early 2026, Green is betting human genetics can do for ALS what it did for heart failure.
Maneesh Jain is the CEO and Co-founder of Mirvie, a South San Francisco-based biotech company pioneering RNA-based blood tests to predict pregnancy complications like preeclampsia and preterm birth months before symptoms occur. A serial entrepreneur with 20+ years in life sciences and more than $1.5B in combined exits across five prior startups - including Ion Torrent (acquired by Life Technologies) and Cirina (acquired by GRAIL) - Jain trained at the Stanford Genome Technology Center and holds a BS from Caltech and a Master's in Applied Physics from Stanford. Mirvie has raised over $90 million from investors including Khosla Ventures, GV, General Catalyst, and the Gates Foundation, and received FDA Breakthrough Device Designation for its preeclampsia risk test in 2022.
Stig K. Hansen is a Danish-American biochemist and serial biotech founder who co-founded Kimia Therapeutics in 2023, a Berkeley-based precision chemistry company applying machine learning and automated synthesis to drug discovery. He previously co-founded and led Carmot Therapeutics for 15 years, inventing Chemotype Evolution technology that contributed to LUMAKRAS - the world's first FDA-approved KRAS G12C inhibitor for non-small cell lung cancer. Carmot was acquired by Roche for up to $3.1 billion in January 2024. At Kimia, Hansen is pioneering the ATLAS platform (AcTive Learning with Automated Synthesis and Screening), which integrates high-throughput chemistry, genome editing, and AI to map druggable chemical space at unprecedented scale. The company raised a $55 million Series A in December 2023 led by The Column Group and Dimension.
Tom Willis, PhD, is a genomics entrepreneur with more than 20 years of company-building experience who became CEO of Arima Genomics in June 2025. A Yale and Stanford physicist turned biotech serial founder, he co-invented Molecular Inversion Probe technology, built two genomics companies from the ground up - ParAllele BioScience (acquired by Affymetrix) and Sequenta (whose ClonoSEQ assay became NCCN-standard for leukemia and lymphoma residual disease testing) - then spent a decade as Venture Partner at Illumina Ventures before stepping in to lead Arima, a company pioneering 3D genomics for cancer diagnostics.
Christina Smolke is the CEO and Co-Founder of Antheia, Inc., a Menlo Park-based synthetic biology company programming yeast to manufacture complex pharmaceutical ingredients — including the active ingredient in Narcan — in days rather than the years required by traditional plant cultivation. A Stanford professor turned biotech entrepreneur, she pioneered the engineering of baker's yeast to produce opioids and other plant-derived medicines, raising over $175 million to bring her lab breakthroughs to global pharmaceutical supply chains.
David J. Lockhart, Ph.D. is President and Chief Scientific Officer of ReCode Therapeutics, a clinical-stage biotech pioneering nonviral lipid nanoparticle (LNP) delivery of mRNA and gene-editing payloads to the lungs for genetic respiratory diseases including cystic fibrosis and primary ciliary dyskinesia. With more than 25 years in drug discovery and genomics — from co-founding Ambit Biosciences to leading science at Amicus Therapeutics — Lockhart brings rare-disease chops and deep genomics expertise to ReCode's SORT LNP platform, which has raised $345M and dosed its first patients in a Phase 1 PCD trial.
Noor Siddiqui is the founder and CEO of Orchid Health, a San Francisco-based biotech startup offering whole-genome sequencing for IVF embryos, screening for 1,200+ genetic variants. Motivated by watching her mother lose her sight to retinitis pigmentosa, she dropped out of high school at 17 to become one of the youngest Thiel Fellows, later returned to earn dual CS degrees at Stanford, and then built Orchid with $16.5M in funding from investors including 23andMe founder Anne Wojcicki and Coinbase's Brian Armstrong. She is also the host of the podcast 'Conceivable with Noor.'
Jorge Conde is a General Partner on the Bio + Health team at Andreessen Horowitz (a16z), where he invests at the intersection of biology, computer science, and engineering. Born in Miami to Cuban and Peruvian parents, Conde co-founded Knome — the first company to offer whole-genome sequencing directly to consumers — alongside Harvard geneticist George Church, then spent years as CSO, CFO, and CPO at Syros Pharmaceuticals before joining a16z in 2017. An MIT Technology Review Innovator Under 35 and Henry Crown Fellow at the Aspen Institute, he is one of the most prominent voices arguing that the 21st century belongs to biology the way the 20th belonged to physics.
Nessan Bermingham, Ph.D., is a serial biotech entrepreneur and Operating Partner at Khosla Ventures who has co-founded eight biotechnology companies including Intellia Therapeutics - one of the first public CRISPR gene editing companies - which he built from concept to IPO in under two years. A child of an Irish Army officer raised on a military base in Co. Kildare, he traded academia for Wall Street, Wall Street for venture capital, and venture capital for founding the companies reshaping genetic medicine. Today he shepherds a portfolio of cutting-edge biotech companies at Khosla Ventures while pursuing 155-mile ultra-marathons and aspiring to race at Dakar.
Samir Kaul is a Founding General Partner at Khosla Ventures who cut the first and largest check into OpenAI before the world knew what a language model could do. A former genomics researcher who co-authored the landmark Arabidopsis genome paper in Nature, he brings a rare scientist's rigor to venture capital - betting on technical risk, not market risk. His portfolio spans Guardant Health, Nutanix, Impossible Foods, and Varda Space Industries, and his philosophy is deceptively simple: find visionary founders attacking large markets with real technology.